Adverse Event Reporting Systems - Epidemiology

Relevant Publications

Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance.

Issue Release: 2025

Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data.

Issue Release: 2024

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.

Issue Release: 2024

JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022-2023.

Issue Release: 2024

A scoping review of the methodological approaches used in retrospective chart reviews to validate adverse event rates in administrative data.

Issue Release: 2024

Analysis of Inclisiran in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and Sex-specific Subgroups.

Issue Release: 2024

A Pharmacovigilance Study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration adverse event reporting system (FAERS) database.

Issue Release: 2024

An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database.

Issue Release: 2024

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.

Issue Release: 2024

Toward a responsible future: recommendations for AI-enabled clinical decision support.

Issue Release: 2024

SMS-Based Active Surveillance of Adverse Events following Immunization in Children: The VigiVax Study.

Issue Release: 2024

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database.

Issue Release: 2024

Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer\'s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System.

Issue Release: 2024

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.

Issue Release: 2024

ORENITRAM\'s decadal journey: unveiling safety profiles and adverse event through a real-world pharmacovigilance study of FAERS events.

Issue Release: 2024

Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.

Issue Release: 2024

A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS).

Issue Release: 2024

Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database.

Issue Release: 2024

Adverse impacts in residential aged care facilities: The resident perspective.

Issue Release: 2024

Analyzing the Barriers of Incident Reporting in MRI Practice in Government Hospitals of Saudi Arabia.

Issue Release: 2024

How Can Diagnostic Services be Improved?

How Do PRNGs Work?

What Role Do Human Activities Play?

Why Are Long Term Health Benefits Important?

How Does Land Use Impact Health?

What are the Advantages of IGRAs Over TST?

What Are the Key Components of Food Safety Standards?

Why Are Geographic Patterns Important?

What are Macular Holes?

What are the Challenges in Meta-Analysis?

Partnered Content Networks

Relevant Topics